EMA Scraps Review of Eli Lilly’s COVID-19 Antibody Therapy

The European Medicines Agency (EMA) has stopped its rolling review of Eli Lilly’s COVID-19 antibody cocktail after the drugmaker withdrew its request because of the lack of demand among EU member states.

In its letter to the EMA, Lilly said insufficient demand meant the company wasn’t “in a position to generate the additional data required … to progress to a formal marketing authorization application.”

The announcement came just one day after the U.S. government purchased a further 614,000 doses of Eli Lilly’s COVID-19 therapy, bamlanivimab and etesevimab, for $1.29 billion.